CareDx Bundle
Who Owns CareDx?
Understanding the ownership of a company like CareDx, Inc. is key to grasping its strategic direction and governance. Its IPO in July 2014 was a major turning point, shifting influence over this molecular diagnostics leader.
CareDx, founded in 1998, is a precision medicine company focused on transplant patient care. As of August 18, 2025, its market capitalization stood at approximately $631 million, following $333.8 million in full-year 2024 revenue.
Who holds the reins at CareDx?
Who Founded CareDx?
CareDx's origins trace back to its incorporation in Delaware on December 21, 1998, initially known as Hippocratic Engineering, Inc. Founded in Palo Alto, California, by Dr. John Scandling and Dr. Minnie Sarwal, the company was established to address critical needs in organ transplant diagnostics and improve patient outcomes.
| Founding Year | Initial Name | Founders | Incorporation State | Headquarters |
|---|---|---|---|---|
| 1998 | Hippocratic Engineering, Inc. | Dr. John Scandling, Dr. Minnie Sarwal | Delaware | Palo Alto, California |
Visionary Founders
Dr. John Scandling and Dr. Minnie Sarwal envisioned enhancing organ transplantation through advanced diagnostic solutions. Their expertise aimed to bridge a gap in patient care.
Early Funding Landscape
The company secured significant early-stage funding, totaling $103 million across 14 rounds. Venture capital firms were primary investors, with Kleiner Perkins Caufield & Byers being a notable participant.
Brand Evolution
In March 2014, Hippocratic Engineering, Inc. officially rebranded as CareDx, Inc. This name change signified a refined focus on its core business within the organ transplant diagnostics market.
Founder Ownership Details
Specific equity splits for the founders at inception are not publicly disclosed. The substantial venture capital backing suggests a significant portion of early ownership was allocated to investment firms.
Absence of Early Disputes
There is no publicly available information indicating any early ownership disputes, vesting schedule complexities, or buy-sell agreements from the company's initial stages.
Strategic Market Focus
The company's strategic direction has consistently centered on improving diagnostics for organ transplantation. Understanding the Target Market of CareDx is key to its business model.
The early ownership structure of CareDx was heavily influenced by its reliance on venture capital. While the founders, Dr. John Scandling and Dr. Minnie Sarwal, were instrumental in its inception and vision, the substantial capital infusions from firms like Kleiner Perkins Caufield & Byers would have resulted in these investors holding significant equity stakes in the company during its formative years. This is a common characteristic of venture-backed startups aiming for rapid growth and market penetration.
Key Aspects of Early Ownership
The initial phase of CareDx's ownership was shaped by its need for external funding to fuel its innovative diagnostic solutions. This led to a distribution of equity among early investors.
- Founders: Dr. John Scandling and Dr. Minnie Sarwal established the company's core mission.
- Venture Capital: Significant investment from firms like Kleiner Perkins Caufield & Byers was crucial.
- Total Early Funding: Approximately $103 million was raised across 14 funding rounds.
- Ownership Distribution: A substantial portion of early ownership was likely held by venture capital investors.
- Public Trading Status: CareDx is a publicly traded company, meaning its stock is available for purchase on exchanges.
CareDx SWOT Analysis
- Complete SWOT Breakdown
- Fully Customizable
- Editable in Excel & Word
- Professional Formatting
- Investor-Ready Format
How Has CareDx’s Ownership Changed Over Time?
CareDx transitioned to public ownership with its IPO on July 16, 2014, listing on NASDAQ under 'CDNA'. This move broadened its investor base, significantly impacting its corporate structure and the distribution of CareDx ownership. The company has since grown through strategic acquisitions, further shaping who owns CareDx.
| Shareholder Type | Percentage of Ownership | Number of Shares (as of August 18, 2025) |
| Institutional Investors | 49.54% | Approximately 28,000,000 |
| Insiders | 9.42% | Approximately 5,000,000 |
| Public Companies & Individual Investors | 41.04% | Approximately 20,200,000 |
The ownership evolution of CareDx has been significantly influenced by its strategic growth initiatives, including key acquisitions that have expanded its product offerings and market presence. These developments are crucial for understanding the current CareDx stock ownership and identifying CareDx major shareholders.
Major Institutional Investors in CareDx
Institutional investors hold a significant portion of CareDx, indicating substantial backing from large financial entities. These stakeholders play a vital role in the company's governance and strategic direction.
- Vanguard Group Inc. holds approximately 6.93% of institutional holdings.
- Blackrock, Inc. possesses 4,657,919 shares.
- Invesco Ltd. owns 2,543,419 shares.
- ARK Investment Management Llc has 2,100,157 shares.
- Bamco Inc /Ny/ holds 2,435,657 shares as of June 30, 2025.
The company's strategic acquisitions, such as AlloSure in 2014, Ottr® and XynManagement in 2019, TXi and AlloCell in 2021, and MediGO in July 2023, reflect a deliberate strategy to diversify its portfolio and strengthen its market position. These moves are key to understanding the Growth Strategy of CareDx and how it impacts CareDx ownership structure explained.
CareDx PESTLE Analysis
- Covers All 6 PESTLE Categories
- No Research Needed – Save Hours of Work
- Built by Experts, Trusted by Consultants
- Instant Download, Ready to Use
- 100% Editable, Fully Customizable
Who Sits on CareDx’s Board?
The Board of Directors at CareDx is instrumental in guiding the company's strategic path and ensuring accountability to its shareholders. As of the 2025 annual meeting, the board comprises both executive and independent directors, with John W. Hanna serving as President and CEO since April 15, 2024, and Michael Goldberg acting as Board Chairperson. This structure aims to provide robust oversight and governance.
| Director Name | Role | Term End (Annual Meeting) |
|---|---|---|
| John W. Hanna | President and Chief Executive Officer (CEO) | |
| Michael Goldberg | Board Chairperson | |
| Dr. Peter Maag | Board Member | |
| Bryan Riggsbee | Board Member, Chair of the Audit and Finance Committee | 2026 |
| Dr. Frederick Cohen | Class II Director | 2026 |
| George Bickerstaff | Committee Member |
CareDx operates under a straightforward one-share-one-vote system, meaning each share of common stock held as of the record date, April 15, 2025, grants its owner a single vote. On this date, there were 55,596,737 shares of common stock outstanding and eligible to vote. The company's corporate structure does not feature dual-class shares or other mechanisms that would concentrate voting power disproportionately. The definitive proxy statement, filed on April 28, 2025, details the voting process for the annual meeting, including proposals for director elections and executive compensation approval, adhering to standard public company governance.
Understanding CareDx Ownership and Governance
The structure of CareDx's board and its voting power are key to understanding who owns CareDx and how its decisions are made. This framework ensures that the company's direction aligns with shareholder interests.
- CareDx adheres to a one-share-one-vote principle.
- The board composition includes executive and independent directors.
- Voting power is directly tied to the number of shares held.
- The company's proxy statement provides detailed information on shareholder voting.
- Understanding CareDx stock ownership is crucial for investors.
CareDx Business Model Canvas
- Complete 9-Block Business Model Canvas
- Effortlessly Communicate Your Business Strategy
- Investor-Ready BMC Format
- 100% Editable and Customizable
- Clear and Structured Layout
What Recent Changes Have Shaped CareDx’s Ownership Landscape?
Over the past few years, CareDx's ownership landscape has been shaped by strategic financial decisions and significant legal outcomes. The company's share repurchase program and recent legal settlements have had a direct impact on its outstanding shares and overall corporate structure.
| Development | Date | Impact on Ownership |
| Common Stock Repurchase Program Authorized | February 2025 | Reduces outstanding shares, potentially increasing proportional ownership for existing shareholders. |
| Stock Repurchased | Q2 2025 | Approximately $50 million worth of stock bought back. |
| DOJ Investigation Cleared | Early 2024 | Removed legal uncertainty, potentially influencing investor confidence. |
| Patent Litigation Judgment Overturned | February 2025 | Eliminated a significant financial liability, impacting the company's financial health and investor perception. |
| Class Action Lawsuit Settlement | April 2025 | Resulted in an out-of-pocket cost of $5.4 million, impacting Q1 2025 financials. |
| New CFO Appointed | August 2025 | Leadership change that may influence strategic financial decisions and investor relations. |
Institutional investors play a substantial role in CareDx's shareholder base, reflecting a broader trend in the healthcare diagnostics sector. While founder dilution is a common occurrence in publicly traded companies, insider ownership at CareDx stands at approximately 9.42%. The company has set ambitious financial goals, targeting $500 million in revenue and $100 million in adjusted EBITDA by 2027, which could attract further investment and shape future ownership trends. There have been no announcements regarding potential privatization or new public listings.
Institutional Investor Influence
Institutional investors hold a significant portion of CareDx stock. This indicates substantial backing from large financial entities within the healthcare diagnostics industry.
Insider Ownership Levels
Insider ownership at CareDx is approximately 9.42%. This figure represents the stake held by company executives and directors.
Future Financial Targets
The company aims for $500 million in revenue and $100 million in adjusted EBITDA by 2027. These targets could influence future investment and ownership dynamics.
Share Buyback Impact
A $50 million stock repurchase program authorized in February 2025 can alter ownership percentages. This program is expected to be executed over 24 months.
CareDx Porter's Five Forces Analysis
- Covers All 5 Competitive Forces in Detail
- Structured for Consultants, Students, and Founders
- 100% Editable in Microsoft Word & Excel
- Instant Digital Download – Use Immediately
- Compatible with Mac & PC – Fully Unlocked
- What is Brief History of CareDx Company?
- What is Competitive Landscape of CareDx Company?
- What is Growth Strategy and Future Prospects of CareDx Company?
- How Does CareDx Company Work?
- What is Sales and Marketing Strategy of CareDx Company?
- What are Mission Vision & Core Values of CareDx Company?
- What is Customer Demographics and Target Market of CareDx Company?
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.